James W. Smithy, MD, MHS

Real-world studies show TIL therapy drives durable melanoma responses with no new safety concerns, but many patients miss eligibility.

Experts unpack real-world TIL therapy results, who qualifies, and how to sequence lifileucel after immunotherapy or BRAF for metastatic melanoma.